About Bellicum Pharmaceuticals (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BLCM
- CUSIP: N/A
- Web: www.bellicum.com
Capitalization:- Market Cap: $342.56 million
- Outstanding Shares: 33,226,000
Average Prices:- 50 Day Moving Avg: $11.04
- 200 Day Moving Avg: $11.42
- 52 Week Range: $7.41 - $23.11
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.49
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $323,000.00
- Price / Sales: 1,060.56
- Book Value: $3.70 per share
- Price / Book: 2.79
Profitability:- EBITDA: ($79,180,000.00)
- Net Margins: -17,957.31%
- Return on Equity: -70.74%
- Return on Assets: -53.29%
Debt:- Debt-to-Equity Ratio: 0.22%
- Current Ratio: 8.34%
- Quick Ratio: 8.34%
Misc:- Average Volume: 685,265 shs.
- Beta: 1.25
- Short Ratio: 9.65
Frequently Asked Questions for Bellicum Pharmaceuticals (NASDAQ:BLCM)
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its earnings results on Tuesday, August, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period in the previous year, the firm earned ($0.61) EPS. View Bellicum Pharmaceuticals' Earnings History.
When will Bellicum Pharmaceuticals make its next earnings announcement?
Where is Bellicum Pharmaceuticals' stock going? Where will Bellicum Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued 12-month price targets for Bellicum Pharmaceuticals' stock. Their forecasts range from $16.00 to $35.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $26.20 in the next year. View Analyst Ratings for Bellicum Pharmaceuticals.
What are analysts saying about Bellicum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Following Bellicum's 4Q16 earnings conference call, we are reiterating our Overweight rating and $32 price target. Bellicum provided several updates outlining its plans for 2017, including: 1) progress in its current BP-004 trial with BPX-501 in malignant and non-malignant pediatric transplant patients, 2) greater clarity from the FDA on the development path of BPX-501 in the U.S., and 3) updates on its expanding CAR and TCR oncology programs. Looking forward, we expect additional updated data at the European Hematology Association (EHA) meeting being held in June and an update on the finalized U.S. registration trial design in mid-2017." (3/14/2017)
- 2. Jefferies Group LLC analysts commented, "BLCM presented long term data consistent with the ASH 2016 readout, demonstrating low rates of GvHD and relapse. One theme of the meeting we found interesting was the ongoing debate on whether T cells are necessary to prevent BMT complications and relapse. Further, conversations with docs highlighted the discordant strategies for GvHD prevention." (2/27/2017)
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include Adaptimmune Therapeutics PLC (ADAP), MacroGenics (MGNX), Paratek Pharmaceuticals (PRTK), Synergy Pharmaceuticals (SGYP), Axovant Sciences Ltd (AXON), G1 THERAPEUTICS (GTHX), Calithera Biosciences (CALA), Achaogen (AKAO), Madrigal Pharmaceuticals (MDGL), Achillion Pharmaceuticals (ACHN), Insys Therapeutics (INSY), Aurinia Pharmaceuticals (AUPH), Karyopharm Therapeutics (KPTI), Rigel Pharmaceuticals (RIGL), Clementia Pharmaceuticals (CMTA), Selecta Biosciences (SELB), Sucampo Pharmaceuticals (SCMP) and Jounce Therapeutics (JNCE).
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- James Farrell Brown, Independent Chairman of the Board
- Richard A. Fair, President, Chief Executive Officer, Director
- David M. Spencer Ph.D., Founder, Chief Scientific Officer
- Kevin M. Slawin M.D., Founder
- Alan A. Musso CPA, Chief Financial Officer, Treasurer
- Ken Moseley J.D., Senior Vice President, General Counsel, Corporate Secretary
- James M. Daly, Independent Director
- Stephen R. Davis, Independent Director
- Reid M. Huber Ph.D., Independent Director
- Frank B. McGuyer, Independent Director
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.
How do I buy Bellicum Pharmaceuticals stock?
Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $10.31.
MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Bellicum Pharmaceuticals (NASDAQ:BLCM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $26.20 (154.12% upside) |
Consensus Price Target History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Analysts' Ratings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $16.00 | Low |  |
| 8/9/2017 | Raymond James Financial, Inc. | Set Price Target | Buy | $29.00 -> $18.00 | High | |
| 6/27/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $31.00 | Low | |
| 6/26/2017 | Cantor Fitzgerald | Reiterated Rating | Overweight | $35.00 | Low | |
| 6/24/2017 | Ladenburg Thalmann Financial Services | Set Price Target | Buy | $31.00 | Low | |
| 8/9/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $25.00 -> $31.00 | N/A | |
| 8/9/2016 | Citigroup Inc. | Upgrade | Neutral -> Buy | $24.00 | N/A | |
| 6/2/2016 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $20.00 | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)Earnings History by Quarter for Bellicum Pharmaceuticals (NASDAQ BLCM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.73) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.65) | ($0.74) | $0.08 million | | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.70) | ($0.80) | $0.09 million | $0.13 million | View | N/A | |
| 3/13/2017 | Q4 2016 | ($0.71) | ($0.74) | $0.10 million | $0.08 million | View | N/A | |
| 11/9/2016 | Q3 | ($0.63) | ($0.66) | $0.09 million | $0.11 million | View | N/A | |
| 8/8/2016 | Q216 | ($0.57) | ($0.61) | $0.10 million | $0.10 million | View | Listen | |
| 3/14/2016 | Q415 | ($0.44) | ($0.63) | $2.00 million | $0.03 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.38) | ($0.51) | $0.18 million | $0.06 million | View | N/A | |
| 8/13/2015 | Q215 | ($0.49) | ($0.40) | $0.23 million | $0.08 million | View | Listen | |
| 5/11/2015 | Q1 | ($0.22) | ($0.30) | $0.50 million | $0.11 million | View | N/A | |
| 3/11/2015 | Q4 | ($11.79) | ($2.02) | $0.60 million | $0.02 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)2017 EPS Consensus Estimate: ($2.88)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.72) | ($0.71) | ($0.72) |
| Q2 2017 | 2 | ($0.67) | ($0.63) | ($0.65) |
| Q3 2017 | 2 | ($0.76) | ($0.74) | ($0.75) |
| Q4 2017 | 2 | ($0.79) | ($0.74) | ($0.77) |
(Data provided by Zacks Investment Research)
Dividend History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Bellicum Pharmaceuticals (NASDAQ:BLCM)Insider Ownership Percentage: 18.77%
Institutional Ownership Percentage: 55.74%
Insider Trades by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/24/2017 | Alan K. Smith | EVP | Sell | 437 | $11.85 | $5,178.45 | |
| 7/13/2017 | Ken Moseley | VP | Sell | 13,823 | $12.26 | $169,469.98 | |
| 7/10/2017 | David M. Spencer | Insider | Sell | 10,000 | $11.54 | $115,400.00 | |
| 5/25/2017 | Alan A. Musso | CFO | Sell | 6,311 | $12.24 | $77,246.64 | |
| 3/24/2017 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 166,666 | $12.00 | $1,999,992.00 | |
| 2/7/2017 | Kevin M Slawin | Director | Sell | 30,000 | $12.54 | $376,200.00 | |
| 12/15/2016 | Kevin M Slawin | Insider | Sell | 30,000 | $15.45 | $463,500.00 | |
| 12/5/2016 | David M Spencer | Insider | Sell | 5,000 | $20.00 | $100,000.00 | |
| 12/1/2016 | Annemarie Moseley | COO | Sell | 25,000 | $17.54 | $438,500.00 | |
| 11/28/2016 | Alan A. Musso | CFO | Sell | 29,300 | $19.51 | $571,643.00 | |
| 9/23/2016 | Ken Moseley | VP | Sell | 11,800 | $20.10 | $237,180.00 | |
| 9/23/2016 | Kevin M Slawin | Insider | Sell | 23,416 | $20.12 | $471,129.92 | |
| 9/20/2016 | David M Spencer | Insider | Sell | 2,500 | $20.01 | $50,025.00 | |
| 9/20/2016 | Ken Moseley | VP | Sell | 2,200 | $20.01 | $44,022.00 | |
| 8/15/2016 | Ken Moseley | VP | Sell | 1,000 | $20.00 | $20,000.00 | |
| 8/15/2016 | Kevin M Slawin | Insider | Sell | 67,000 | $19.31 | $1,293,770.00 | |
| 7/27/2016 | David M. Spencer | Insider | Sell | 10,000 | $15.00 | $150,000.00 | |
| 7/18/2016 | Kevin M Slawin | CTO | Sell | 2,719 | $13.99 | $38,038.81 | |
| 7/15/2016 | Kevin M Slawin | CTO | Sell | 22,281 | $13.72 | $305,695.32 | |
| 6/2/2016 | Annemarie Moseley | COO | Sell | 25,000 | $13.00 | $325,000.00 | |
| 6/2/2016 | Ken Moseley | VP | Sell | 15,000 | $13.00 | $195,000.00 | |
| 4/22/2016 | Kevin M Slawin | CTO | Sell | 55,000 | $11.43 | $628,650.00 | |
| 1/4/2016 | Annemarie Moseley | COO | Sell | 35,000 | $19.07 | $667,450.00 | |
| 12/1/2015 | David M Spencer | Insider | Sell | 5,000 | $22.95 | $114,750.00 | |
| 11/24/2015 | Alan A Musso | CFO | Sell | 29,300 | $22.34 | $654,562.00 | |
| 11/2/2015 | Ken Moseley | VP | Sell | 15,000 | $13.00 | $195,000.00 | |
| 10/1/2015 | Thomas J Farrell | CEO | Sell | 2,500 | $14.58 | $36,450.00 | |
| 9/11/2015 | David M Spencer | Insider | Sell | 5,000 | $19.00 | $95,000.00 | |
| 9/1/2015 | Thomas J Farrell | CEO | Sell | 2,500 | $16.78 | $41,950.00 | |
| 7/15/2015 | Kevin M Slawin | CTO | Sell | 6,000 | $20.00 | $120,000.00 | |
| 6/16/2015 | David M Spencer | Insider | Sell | 20,000 | $22.96 | $459,200.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Latest Headlines for Bellicum Pharmaceuticals (NASDAQ:BLCM)
| Source: |
|
| Date | Headline |
|---|
 | Analyzing Bellicum Pharmaceuticals (BLCM) & Aurinia Pharmaceuticals (AUPH)
www.americanbankingnews.com - October 18 at 10:42 PM |
| Bellicum Pharmaceuticals, Inc. (BLCM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 4 at 9:08 AM |
| Brokerages Anticipate Bellicum Pharmaceuticals, Inc. (BLCM) Will Post Earnings of -$0.72 Per Share
www.americanbankingnews.com - October 1 at 4:28 AM |
 | TapImmune's new CEO shares the potential of cancer immunotherapies
www.bizjournals.com - September 29 at 11:02 AM |
 | Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
www.fool.com - September 28 at 2:41 PM |
| Local biopharmaceutical company names new CEO
www.bizjournals.com - September 25 at 8:11 PM |
| Financial Analysis: Bellicum Pharmaceuticals (BLCM) vs. The Competition
www.americanbankingnews.com - September 17 at 12:30 AM |
| Bellicum Pharmaceuticals, Inc. (BLCM) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - September 14 at 7:16 PM |
| Brokerages Expect Bellicum Pharmaceuticals, Inc. (BLCM) Will Post Quarterly Sales of $70,000.00
www.americanbankingnews.com - September 14 at 8:20 AM |
| -$0.72 EPS Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - September 12 at 10:14 AM |
| Analyzing Bellicum Pharmaceuticals (BLCM) and its Competitors
www.americanbankingnews.com - September 12 at 4:26 AM |
 | Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : September 11, 2017
finance.yahoo.com - September 11 at 5:15 PM |
| Bellicum Pharmaceuticals, Inc. (BLCM) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 9 at 9:30 AM |
| Bellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : September 6, 2017
finance.yahoo.com - September 5 at 11:13 PM |
| Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : September 1, 2017
finance.yahoo.com - September 1 at 4:51 PM |
| Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
finance.yahoo.com - August 30 at 5:52 PM |
 | Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI - TheStreet.com
www.thestreet.com - August 29 at 9:59 PM |
 | Bellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher - Nasdaq
www.nasdaq.com - August 29 at 4:58 PM |
| Bellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher
finance.yahoo.com - August 29 at 4:58 PM |
| Research Analysts Set Expectations for Bellicum Pharmaceuticals, Inc.'s FY2017 Earnings (BLCM)
www.americanbankingnews.com - August 28 at 3:18 AM |
| $70,000.00 in Sales Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - August 26 at 1:30 AM |
| -$0.72 Earnings Per Share Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - August 24 at 10:24 PM |
 | Bellicum Offers A Promising Stock At Throwaway Prices
seekingalpha.com - August 17 at 5:58 PM |
 | Bellicum Pharma (BLCM) Enters Cancer Research Grant Contract with CPRIT
www.streetinsider.com - August 16 at 3:29 AM |
| Bellicum Pharma (BLCM) Enters Cancer Research Grant Contract with CPRIT - StreetInsider.com
www.streetinsider.com - August 15 at 5:24 PM |
| Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 15 at 6:32 AM |
| Q3 2017 EPS Estimates for Bellicum Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:BLCM)
www.americanbankingnews.com - August 11 at 9:48 AM |
| SunTrust Banks Analysts Reduce Earnings Estimates for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
www.americanbankingnews.com - August 11 at 9:48 AM |
| Houston pharma co. shakes up C-suite again
finance.yahoo.com - August 10 at 5:47 PM |
| Bellicum Pharmaceuticals, Inc. (BLCM) Announces Earnings Results
www.americanbankingnews.com - August 9 at 10:04 PM |
| Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - August 9 at 4:46 PM |
 | 22 Biggest Mid-Day Losers For Wednesday - Benzinga
www.benzinga.com - August 9 at 4:46 PM |
| Edited Transcript of BLCM earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 4:46 PM |
 | Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 8 at 4:20 PM |
| Investor Network: Bellicum Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 4:20 PM |
| Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 4:20 PM |
| Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Expected to Announce Quarterly Sales of $80,000.00
www.americanbankingnews.com - August 8 at 7:44 AM |
| Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:06 AM |
| Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer
finance.yahoo.com - August 3 at 6:03 PM |
| Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017
feeds.benzinga.com - August 1 at 7:23 AM |
| Bellicum Pharmaceuticals, Inc. (BLCM) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:10 AM |
| Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : July 28, 2017
finance.yahoo.com - July 28 at 6:02 PM |
| ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 3:54 PM |
| Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 21 at 9:18 AM |
| Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Expected to Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - July 19 at 3:02 PM |
| Bellicum Pharmaceuticals, Inc. (BLCM) VP Sells $169,469.98 in Stock
www.americanbankingnews.com - July 17 at 7:15 PM |
| Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : July 14, 2017
finance.yahoo.com - July 14 at 11:34 PM |
| ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 11:34 PM |
| David M. Spencer Sells 10,000 Shares of Bellicum Pharmaceuticals, Inc. (BLCM) Stock
www.americanbankingnews.com - July 12 at 8:17 PM |
| Bellicum Pharmaceuticals: A Story Of Hype And Hope - Seeking Alpha
seekingalpha.com - July 5 at 5:16 PM |
Bellicum Pharmaceuticals (BLCM) Chart for Thursday, October, 19, 2017
